There were early hopes that the drug Aducanumab (from Biogen) might be able to slow down the build-up of amyloid protein in the brain, but trials were halted in March 2019 due to “disappointing” trial results. Subsequent re-analysis of the data has, surprisingly, indicated some benefit for patients in the earliest stages of Alzheimer’s Disease, when the drug is given at higher dosage levels.
“ …a new analysis of a larger dataset of the same studies shows that higher doses of aducanumab can provide a significant benefit to patients with early Alzheimer’s, slowing their clinical decline so they preserve more of their memory and every day living skills”.
The drug approval process in different countries could take several years and is by no means certain.
Roberts, M. (2019). First drug that can slow Alzheimer’s dementia. London: BBC Health News, October 22nd 2019.